On July 3, GlaxoSmithKline and CureVac drafted a new licensing agreement for the mRNA vaccine collaboration agreement that gives GlaxoSmithKline all rights to develop flu and COVID-19 candidate vaccines (including combination vaccines). CureVac will receive a prepayment of 400 million euros, as well as up to 1.05 billion euros in milestones and royalties. CureVac retains exclusive rights to other undisclosed and clinically unvalidated infectious disease targets in previous collaborations, as well as the freedom to independently develop and collaborate in the development of mRNA vaccines in any other infectious disease or other therapeutic areas. CureVac's ongoing patent litigation against Pfizer/BioNTech is unaffected by the new agreement.
葛兰素史克与Curevac重新拟定mRNA疫苗合作协议
GlaxoSmithKline and curevac have redrafted their mRNA vaccine collaboration agreement
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.